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Abstract
Prostate cancer remains a significant public health problem, with limited therapeutic options in the setting of cas-
trate-resistant metastatic disease. Angiogenesis inhibition is a relatively novel antineoplastic approach, which targets
the reliance of tumor growth on the formation of new blood vessels. This strategy has been used successfully in
other solid tumor types, with the FDA approval of anti-angiogenic agents in breast, lung, colon, brain, and kidney
cancer. The application of anti-angiogenic therapy to prostate cancer is reviewed in this article, with attention to
efficacy and toxicity results from several classes of anti-angiogenic agents. Ultimately, the fate of anti-angiogenic
agents in prostate cancer rests on the eagerly anticipated results of several key phase III studies.
Introduction
Prostate cancer, the second leading cause of cancer-
related death in males, remains a major public health
concern. Most cases of prostate cancer present with
localized disease and may be cured with treatments
such as surgery and radiation. However, as is true with
most solid malignancies, the development of metastatic
disease is ultimately lethal. Despite active systemic
therapies, the metastatic phenotype is marked by the
inevitable development of resistance, disease progres-
sion, and ultimately, death. Moreover, systemic treat-
ments in prostate cancer are limited. Until recently,
there were only three chemotherapeutic agents FDA-
approved for use in castrate-resistant prostate cancer
(estramustine, mitoxantrone, and docetaxel), with the
most recent approval in 2004 [1-5]. Although 2010 is
already notable for the approval of two additional agents
for prostate cancer (sipuleucel-T and cabazitaxel) [1],
there is still a clear need to develop additional systemic
options in this deadly disease.
The observation of Dr. Judah Folkman that tumors
are unable to grow more than 2-3 millimeters in the
absence of neo-vascularization laid the foundation for
the field of anti-angiogenic cancer therapy [6]. In addi-
tion, the observation that the process of angiogenesis
could be stimulated by a diffusible substance released
by tumor cells ultimately led to the identification of
angiogenic factors which could be targeted for thera-
peutic use. After decades of active investigation, anti-
angiogenic agents have finally reached the clinic. The
first of these drugs to be FDA-approved is bevacizumab,
which has now been approved for use in colon cancer,
lung cancer, breast cancer, kidney cancer and glioblas-
toma [7-13]. To date, no anti-angiogenic agents have
been approved for use in prostate cancer although
clinical trials have suggested activity in this disease. The
scope of this review is to provide an overview of mole-
cular targets that are key components of angiogenic
signaling and to discuss the results of anti-angiogenesis
agents in prostate cancer clinical trials.
Rationale for the use of angiogenesis inhibitors in cancer
Angiogenesis, or the process of new blood vessel forma-
tion, is necessary during cancer progression. Because
growth of a tumor is dependent on the diffusion of
nutrients and wastes, establishing a blood supply is criti-
cal for continued tumor enlargement. The limitation of
nutrient diffusion is the reason why tumors are unable
to grow larger than 2-3 mm in the absence of neovascu-
larization. The transition of a tumor from this avascular
state to acquiring the ability to promote the growth of
new blood vessels has been termed the “angiogenic
switch.” This discrete change is a critical step in tumor
progression.
Several processes have been described which compose
the angiogenic switch [reviewed in [14]]. The endothelial
cells that line existing blood vessels are activated,
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resulting in invasive, migratory, and proliferative proper-
ties. The basement membrane of the existing blood ves-
sel and the surrounding extracellular matrix is degraded,
allowing endothelial cell precursors to migrate toward
the angiogenic stimulus. Endothelial cells proliferate and
line the migration column. Capillary tubes are ultimately
formed by the remodeling and re-adhesion of the
endothelial cells, supported and stabilized by surround-
ing periendothelial cells and vascular smooth muscle
cells.
The process of angiogenesis is stimulated by various
angiogenic factors which are present in tumor and
tumor-associated stroma. Although the most widely stu-
died of these angiogenic factors is vascular endothelial
growth factor-A (VEGF-A), the list of angiogenic activa-
tors includes other molecules such as placental growth
factor, angiopoeitin-1, fibroblast growth factors, platelet-
derived growth factor, epidermal growth factor and lyso-
phosphatic acid. In addition, angiogenesis is inhibited by
a number of naturally-occurring anti-angiogenic factors,
which include thrombospondin-1, angiostatin, endosta-
tin, tumstatin and canstatin. The balance of pro and
anti-angiogenic factors is what ultimately determines the
state of the angiogenic switch.
VEGF-A remains the best understood, and perhaps
the most ubiquitous, of the pro-angiogenic growth fac-
tors [15]. As the name implies, members of the VEGF
family act as growth factors, classically on vascular
endothelial cells. VEGF-A is the prototypical member of
the VEGF family of growth factors, which also includes
placenta growth factor, VEGF-B, VEGF-C and VEGF-D.
The VEGF family, in turn, is a sub-group of the plate-
let-derived growth factor family of cystine-knot growth
factors. Members of the VEGF family act as ligands
which bind to members of the VEGF receptor (VEGFR)
family. There are three subtypes of the VEGFR family,
and most of the known cellular responses appear to be
mediated by VEGFR-2. VEGFR-3 appears to have a role
in lymphangiogenesis; while VEGFR-1 may modulate
VEGFR-2 signaling. In addition, VEGF ligands also bind
to neuropilin receptors although the significance of this
interaction is not as clearly understood. When VEGF
ligand binds to VEGFR, downstream signaling is
mediated through dimerization of the receptor and sub-
sequent phosphorylation of receptor tyrosine residues.
This activation results in multiple downstream signals
that ultimately drive the angiogenesis process. The cellu-
lar effects of VEGF-A when bound to VEGFR-2 on
endothelial cells include vasodilatation, vascular perme-
ability, mitogenesis, invasive properties and chemotaxis.
VEGF-A is produced both by tumor cells as well as
tumor-associated stromal cells [16], with VEGF-A
expression most clearly induced by hypoxic conditions.
Cells respond to hypoxic conditions through the
modulation of hypoxia-inducible factors (HIFs). HIF-1 is
a highly evolutionarily conserved member of the basic-
helix-loop-helix family of transcription factors [17]. HIF-
1 is a heterodimer that contains an alpha and a beta
subunit (HIF-1a and HIF-b). HIF-1a is hydroxylated by
HIF prolyl-hydroxylase, which then targets HIF-1a for
degradation under normoxic conditions. Hydroxylated
HIF-1a is specifically ubiquitinated by the VHL E3 ubi-
quitin ligase, marking HIF-1a for proteasomal degrada-
tion. Under hypoxic conditions, the hydroxylation of
HIF-1a is limited by the availability of oxygen molecules
and HIF-1a is stabilized and accumulates. HIF-1a can
then dimerize with HIF-b and induce the transcription
of hypoxia-survival genes. Among the transcripts regu-
lated by HIF-1 is VEGF, which allows tissues to adapt to
hypoxic conditions by promoting angiogenesis.
Although VEGF signaling has been the most closely
associated with tumor angiogenesis, special mention will
also be made here regarding PDGF pathways, because of
the availability of clinical agents that modify PDGF sig-
naling. Similar to VEGF, members of the PDGF family
of growth factors dimerize and interact with members
of the PDGF-R family of tyrosine kinase receptors.
PDGF signaling has been implicated in tumorigenesis
through several mechanisms, including proliferative
autocrine signaling, promotion of invasive and meta-
static behaviors through control of the epithelial-
mesenchymal transition, and paracrine recruitment of
stromal cells, including effects on angiogenesis [reviewed
in [18]]. As a result of these pleotropic effects, PDGF-
targeting agents are being investigated for their potential
as anti-neoplastic therapy [19].
Understanding the mechanisms behind angiogenesis
has led to the availability of novel drugs that target
components of the angiogenesis pathway that are now
being utilized in cancer therapy. The advent of an
entirely new class of anti-cancer therapies has required
an understanding of the differences between angiogen-
esis inhibitors and more conventional chemotherapeutic
agents. The use of angiogenesis inhibitors has been pos-
tulated to have some theoretical advantages and disad-
vantages over traditional chemotherapy. Because most
tissues in a mature organism do not rely on angiogen-
esis, angiogenesis inhibition may have a greater thera-
peutic index than cytotoxic agents, which are also toxic
to many normal cells. This hypothesis has been shown
to be at least partially true when angiogenesis inhibitors
have been studied in clinical trials; investigators have
found that angiogenesis inhibitors have a toxicity profile
that is generally favorable to cytotoxic agents with the
notable exception of unique vascular toxicities.
In addition, it has been argued that because endothe-
lial cells do not possess the genetic instability of
cancer cells, resistance may be less of an issue with
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anti-angiogenesis therapy. As our knowledge and experi-
ence has increased, it has become clear that this was
likely an overly naïve characterization of anti-angiogenic
therapy. Various mechanisms of resistance to angiogen-
esis therapy have been outlined [reviewed in [15,20,21]].
Because of redundancy in angiogenic signals, angiogen-
esis inhibition using a single target can be overcome by
shifting the balance of other pro- and anti-angiogenic
signals. For example, if signal transduction through the
VEGF receptor is targeted, resistance could develop by
tumor overexpression of VEGF. If VEGF is targeted,
tumors may secrete a different pro-angiogenic factor.
Since tumors play a central role in the angiogenic sig-
naling pathways, the genetic instability of the tumor will
contribute to angiogenesis-inhibitor resistance. Clonal
evolution and tumor adaptation may also result in a
tumor that is tolerant of hypoxic conditions and subse-
quently less dependent on neovascularization. In addi-
tion, it has been proposed that hypoxia may select for,
or even induce, clones with greater invasive and meta-
static potential. Acquired tumor resistance may be a
result of evolutionary, genetic, hypoxic or physiologic
changes in tumor biology. Changes in expression of
angiogenic factors by stromal cells are now also felt to
be a key factor in mediating angiogenesis-resistance.
These stromal changes may be mediated by a physiolo-
gic response to hypoxia, by tumor-recruitment of stro-
mal cells, tumor-secretion of stromal-stimulating factors,
or other mechanisms.
One final difference between angiogenesis inhibitors
and cytotoxic therapies that has proven to be critical in
designing and interpreting clinical trials is that angio-
genesis inhibition may arrest tumor growth in a dor-
mant state without tumor regression, because the tumor
cells are not directly targeted. The first implication of
this fact is that traditional endpoints, such as radio-
graphic criteria for measuring response, may not be an
accurate measure of anti-tumor efficacy. In addition, it
has been shown that tumors held in a dormant state by
angiogenesis inhibition can grow vigorously if the inhibi-
tion is released. Thus, there may be a greater role for
maintenance therapy when using angiogenesis inhibitors.
In addition, the question of whether to continue an anti-
angiogenic agent in the face of disease progression
remains an open question.
Evidence for the role of angiogenesis in prostate cancer
pathogenesis
In addition to the evidence that angiogenesis may be
important for tumor growth in general, there is a grow-
ing body of evidence that angiogenesis plays a role in
prostate cancer in particular. It has been demonstrated
that prostate cancer cells express VEGF [22,23] and that
the expression of VEGF by neoplastic cells is greater
than that found in normal prostate stromal tissue.
Moreover, blood and urine VEGF levels have been
shown to correlate with prostate cancer patient out-
comes [24-26]. Markers of neovascularization have also
been shown to have significance in prostate cancer.
Microvessel density has been used as a surrogate histo-
logic measure of angiogenesis within a tumor. Microves-
sel density in prostate cancer has been shown to
correlate strongly with Gleason grade and predicts dis-
ease progression [27,28]. As yet, it has not been shown
definitively that microvessel density can be used as an
independent predictor of patient outcome. Also, whether
neovascularization is the primary pathogenic event, or
whether simply a reflection of the hypoxic conditions
that result from unchecked growth, is unclear from
these histologic correlations. However, this observation
does provide a rationale for further exploring the role of
angiogenesis in prostate cancer progression.
Preclinical data have provided some evidence that
anti-angiogenic therapy is more effective in the setting
of minimal tumor burden. This concept was demon-
strated in a prostate cancer mouse model where VEGFR
antagonists only inhibited tumor progression before
tumors produced significant levels of VEGF [29]. Pros-
tate cancer offers a unique clinical scenario to test the
hypothesis that angiogenesis-inhibition will be more
effective in the setting of minimal disease, because in
the PSA era, disease recurrence is often detected before
metastatic deposits are detectable by imaging modalities
or physical examination.
Clinical trials with anti-angiogenic agents in prostate
cancer
Bevacizumab - VEGF-targeting monoclonal antibody
Bevacizumab is a humanized monoclonal antibody that
recognizes all VEGF isoforms, preventing binding to the
VEGF receptor. It was developed from a murine anti-
human VEGF antibody and retains 7% of the murine
sequence. Single agent bevacizumab was initially evalu-
ated in 15 patients with castrate-resistant cancer [30].
Bevacizumab was given at a dosage of 10 mg/kg every
two weeks for six treatments. Treatment was continued
for patients with either response or stable disease. There
were no patients who had a PSA decline of more than
50%, although four patients out of fifteen had PSA
declines of less than 50%. There were no objective
responses at day 70. The study was thus interpreted as a
negative study and highlights some of the difficulties in
designing and interpreting the results of clinical trials
with anti-angiogenic agents. For anti-angiogenic agents
that are more likely to be cytostatic and not cytotoxic,
radiographic and PSA rates may not be the best mea-
sure of clinical activity. The authors also suggested that
evaluating the activity of angiogenesis inhibitors in
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earlier stages of disease may yield more promising
results. Interestingly, Iacobelli presented a case report of
a patient with castrate-resistant prostate cancer who was
treated with single agent bevacizumab when he refused
chemotherapy [31]. Bevacizumab 7.5 mg/kg every 14
days was used for more than six months with reduction
in PSA from 14 to 4 ng/ml in one month as well as
radiographic response of retroperitoneal lymphadenopa-
thy. Single agent bevacizumab in prostate cancer is cur-
rently being evaluated in patients with biochemical
recurrence to assess the hypothesis that single agent
bevacizumab may have activity in patients with a lesser
burden of disease. In addition to PSA declines of at
least 50%, time to PSA progression is a primary out-
come measure of this study. Change in PSA velocity is a
secondary outcome measure, which may better measure
the cytostatic effects of bevacizumab.
Bevacizumab has also been studied in combination
with cytotoxic agents in prostate cancer. A cooperative
group study, CALGB 90006, used bevacizumab in com-
bination with docetaxel and estramustine [32,33] in
prostate cancer patients who were chemotherapy-naïve.
Docetaxel was given at 70 mg/m2 every three weeks in
combination with estramustine 280 mg three times daily
on days one through five. Bevacizumab was given at 15
mg/kg on day 2 of the chemotherapy cycle. 79 patients
were enrolled. Although final results have not been pub-
lished, the study reported a PSA decline of more than
50% in 77% of patients [33]. 42% of patients with mea-
surable disease were noted to have partial response
based on measurable disease. Bevacizumab was also
given in combination with docetaxel in a phase II study
of 20 patients with docetaxel-refractory metastatic pros-
tate cancer [34]. All patients had been previously treated
with both docetaxel and mitoxantrone; many had been
treated with third-line chemotherapy or beyond. Patients
were treated with docetaxel 60 mg/m2 and bevacizumab
10 mg/kg every three weeks. PSA declines of ≥ 50%
were seen in 55% of patients. Objective radiographic
response was seen in three of 8 patients with measur-
able disease. In addition, PSA declines of ≥ 50% and
radiographic responses were observed in patients who
did not respond to initial docetaxel chemotherapy.
From these phase II studies, it was concluded that the
combination of bevacizumab and chemotherapy is rea-
sonably safe and has activity in prostate cancer. The
activity of these bevacizumab regimens compared favor-
ably to historical controls [4,5]. However, because these
were phase II studies, it could not be determined
whether the addition of the anti-angiogenesis agent con-
tributed significantly to the clinical benefit of the regi-
men, since chemotherapy alone also has activity in
prostate cancer and comparison to historical controls
cannot be considered conclusive evidence of benefit.
This question was addressed by a randomized phase III
(CALGB 90401) comparing docetaxel and prednisone to
the combination of docetaxel, prednisone, and bevacizu-
mab in patients who are chemotherapy-naïve. Enroll-
ment on this clinical trial was completed in early 2008
and results were recently reported in abstract form [35].
This study randomized 1050 patients with chemother-
apy-naïve, metastatic castrate-resistant prostate cancer
(mCRPC) to receive docetaxel plus prednisone (doce-
taxel 75 mg/m2 on day 1; prednisone 5 mg po BID)
with either bevacizumab 15 mg/kg or placebo given on
day 1 of a 21-day cycle. The study did not meet its pri-
mary endpoint of overall survival, and the bevacizumab
arm was notable for a higher rate of both treatment-
related toxicity and mortality. The rate of grade 3
adverse events in the bevacizumab arm was 74.8% com-
pared to 55.3% in the placebo arm (p < 0.001). In addi-
tion, there was a 4.4% toxic death rate on the
bevacizumab arm, compared to a rate of 1.1% in the pla-
cebo arm (p = 0.0014). A majority of the treatment-
related deaths were related to infection. However, it is
important to point out that the bevacizumab arm was
superior in several measures of anti-cancer efficacy: pro-
gression-free survival, rates of ≥ 50% PSA decline, and
objective response rate. The median progression-free
survival was 9.9 months on the experimental bevacizu-
mab arm and 7.5 months on the control arm (p <
0.0001). The PSA response rate was 69.5% in the experi-
mental arm, compared to 57.9% on the control arm,
with a p value of 0.0002. Finally, there was also a statis-
tically significant benefit of bevacizumab in the measur-
able disease response rate (53.2% vs. 42.1%, p = 0.0113).
Although there was a trend for an improvement in
overall survival in the bevacizumab arm (22.6 vs. 21.5
months, p = 0.181), this difference was not statistically
significant. Several reasons have been suggested to
explain the discordance between the overall survival and
progression-free survival endpoints. To begin, the med-
ian overall survival in the control arm was 21.5 months,
which is longer than previously reported studies. The
selection of healthier patients, perhaps earlier in their
disease course, has been attributed to patient and physi-
cian enthusiasm. The improved overall survival in the
control arm may have limited the ability to detect a
treatment effect because of reduced statistical power. In
addition, preliminary subset analysis suggested a more
pronounced overall survival effect in patients with
poorer prognosis (lower hemoglobin, higher alkaline
phosphatase, elevated LDH). Thus, the selection of gen-
erally healthier patients may have masked any effect of
bevacizumab on overall survival, in addition to limiting
the statistical power of the study. Secondly, duration of
therapy has been cited as an important contributor to
treatment-efficacy, especially with anti-angiogenic
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therapy. The median number of treatment cycles was
only 8 cycles, compared to 9.5 cycles on the TAX 327
study [4]. Because the trial was designed prior to
consensus recommendations discouraging treatment-
discontinuation for isolated PSA progression in the
absence of clinical progression, it is possible that bevaci-
zumab was discontinued prematurely on the basis of
PSA progression alone. The effect of premature discon-
tinuation would be compounded by the postulated
aggressive “rebound” phenomenon that has been
reported to occur upon the discontinuation of anti-an-
giogenic therapies. Finally, the availability of subsequent
therapies, as well as the excess toxicity in the bevacizumab
arm may also have mitigated the effect of bevacizumab on
overall survival in this population.
VEGFR tyrosine kinase inhibitors
As previously mentioned, VEGF ligands stimulate angio-
genesis by binding and activating VEGF tyrosine kinase
receptors. The development of small molecules that
inhibit tyrosine kinases, primarily by binding the ATP
binding domain, has led to investigation of tyrosine
kinase inhibitors as angiogenesis inhibitors. In general,
because tyrosine kinases are involved in many signaling
pathways and the ATP binding sites are relatively con-
served, tyrosine kinase inhibitors may target more than
one receptor pathway that has a role in tumor
progression.
Sorafenib
Several tyrosine kinase inhibitors are known to target
the VEGF tyrosine kinase receptors. Sorafenib is a mul-
tikinase inhibitor that can target tumor cell proliferation
by Raf kinase inhibition, in addition to targeting angio-
genesis by inhibiting the VEGFR-2, VEGFR-3 and
PDGFR kinases. Results of three phase II studies in
prostate cancer have been recently reported. Twenty-
two patients with metastatic androgen independent
prostate cancer were enrolled onto a Phase II NCI-
sponsored study of sorafenib 400 mg twice daily [36]. A
majority of patients (59%) had received at least one che-
motherapy regimen prior to enrolling on this study. No
complete or partial responses were seen. There were no
patients with PSA decline ≥ 50%. Although these mea-
sures of disease activity were negative, PSA declines
were seen after discontinuation of study agent in the
absence of starting any new therapy. In addition, two
patients with rising PSA levels showed resolution of
bone lesions on bone scan. The authors presented data
that sorafenib can result in PSA secretion in vitro,
potentially explaining these results.
The Canadian experience with sorafenib as a single
agent in prostate cancer is similar to the other Phase II
studies [37]. Twenty-eight patients were treated with
sorafenib 400 mg twice daily. PSA progression despite
castrate levels of testosterone was required for eligibility
and prior chemotherapy was not permitted. All but two
patients had evidence of metastatic disease. No patient
had radiographic response using RECIST criteria. Only
one patient (3.6%) had a PSA decline of ≥ 50%, from
10,000 to 1643. However, 10 of 16 patients who did not
receive any post-sorafenib treatment had subsequent
PSA declines. In combination with the previous data
from Dahut et al [36], these clinical observations imply
that PSA progression may not be the best reflection of
disease activity in the setting of sorafenib treatment.
Finally, a European study also reported their Phase II
results with sorafenib as a single agent used at a dose of
400 mg twice daily [38]. In contrast to the NCI study,
the 55 men enrolled on the trial all had chemotherapy-
naïve castrate-resistant prostate cancer. No responses
were seen by RECIST criteria in eight patients with
measurable disease. Two patients had ≥ 50% PSA
declines at 12 weeks. Taken together, sorafenib shows
little clinical activity in prostate cancer as a single agent,
although intriguing evidence regarding PSA increases
due directly to sorafenib may underestimate its effects
on PSA progression. Sorafenib is currently being studied
in earlier stages of disease, as well as in combination
with chemotherapy.
Sunitinib
Sunitinib is another multitargeting tyrosine kinase inhi-
bitor that inhibits VEGF and PDGF receptors, among
others. A case report of a male whose prostate cancer
was being managed by active surveillance while he was
treated with sunitinib for metastatic renal cell carcinoma
showed evidence of both PSA decline ≥ 50% as well as
radiographic and histologic evidence of regression [39].
A more formal phase II study was recently reported by
Michaelson et al [40]. Thirty-four men, half chemother-
apy-naïve and half docetaxel-resistant, were treated with
sunitinib 50 mg daily for four weeks followed by two
weeks rest. All but one patient had metastatic disease.
Sunitinib did not appear to have significant activity
when measured by classic criteria. Only two patients
had PSA decline ≥ 50%; and the best radiographic
response was partial response in one patient. Eighteen
men had stable disease at twelve weeks by RECIST cri-
teria. As seen in the sorafenib studies, PSA decline did
not correlate with radiographic imaging. The sole
patient with partial response by RECIST criteria had a
PSA decline of less than 50%. In addition, patients with
radiographic improvement that did not meet RECIST
criteria for response were noted to have rising PSA
levels. Thus, the activity profile of sunitinib appears to
be similar to that of sorafenib in this setting. The find-
ings of this study again highlight the need for better
markers of clinical benefit in anti-angiogenesis
strategies.
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Thalidomide
Thalidomide was originally marketed as an oral sedative
and anti-emetic drug in the 1950’s. However, it was sub-
sequently withdrawn from the market because of reports
of teratogenicity, including phocomelia and other limb
deformities. Subsequent work suggested that thalido-
mide had anti-angiogenic properties that may be
responsible for its teratogenic effects [41]. Confirming
this hypothesis, thalidomide given to prostate cancer
patients prior to surgery resulted in reduced microvessel
density as well as decreased expression of VEGF and IL-
6 in prostatectomy specimens [42]. Thalidomide also
appeared to affect other components of the tumor
microenvironment without affecting the epithelial com-
ponent itself. Sonic hedgehog signaling and the ratio of
matrix metalloproteinases to E-cadherin were both
reduced, suggesting a less aggressive molecular pheno-
type. The underlying mechanism of angiogenesis inhibi-
tion by thalidomide, as well as its other biologic
activities, is still not entirely understood.
Motivated by the discovery of its anti-angiogenic
effects, thalidomide was studied as a single agent in cas-
trate-resistant prostate cancer [43]. Two dose levels
were planned, but because of tolerability, the majority of
patients were treated at the low dose of 200 mg/day. A
majority of the 63 patients enrolled had metastatic dis-
ease, with a median PSA of 326 ng/mL. 24% of patients
had received previous chemotherapeutic agents.
Response rates to thalidomide were not dramatic, but
thalidomide did show some evidence of activity in this
cohort of patients. Nine patients (14%) had a PSA
decline of ≥ 50% and 17 patients (27%) had at least a
PSA decline of 40%. Because thalidomide was shown to
increase PSA secretion in vitro [44], PSA declines of less
than 50% were felt to be important to report. One
patient had a PSA decline of ≥ 50% that lasted for more
than one year. No objective radiographic responses were
observed.
A randomized Phase III study of thalidomide in
patients with biochemically recurrent, castrate-sensitive
disease treated with intermittent androgen deprivation
was recently reported [45]. 159 patients were enrolled
and were treated with six months of GnRH agonist ther-
apy followed by thalidomide 200 mg daily or placebo. At
the time of progression, patients were restarted on six
months of androgen deprivation and crossed over to the
alternate drug. During both phases of therapy, time to
PSA progression favored the thalidomide group (15 vs.
9.6 months in the first phase; 17.1 vs. 6.6 months in the
second phase). The difference between the groups dur-
ing the second, cross-over, phase was statistically signifi-
cant (p = 0.0002), while the difference in the first phase
of treatment was not statistically significant. The appli-
cation of these findings to clinical practice is limited by
the unclear relationship between PSA progression and
clinical benefit, especially during the treatment of cas-
trate-sensitive prostate cancer with intermittent andro-
gen deprivation.
Thalidomide has also been tested in combination with
chemotherapy in several phase II studies. In a rando-
mized phase II study, 75 patients with metastatic cas-
trate resistant prostate cancer received weekly docetaxel,
30 mg/m2 for three weeks of a four week cycle with or
without thalidomide 200 mg daily [46-48]. In the initial
report of the fully accrued trial, the percentage of
patients with PSA declines ≥ 50% was greater in the
combination arm (53% vs. 37%). Median overall survival
was reported as 14.7 months for docetaxel monotherapy
and 28.9 months in the combination arm. These differ-
ences were not statistically significant when initially
reported; however, updated results demonstrated an
overall survival of 25.9 months on the thalidomide arm
and 14.7 months for the docetaxel monotherapy arm
(p = 0.0407) [48]. A high rate of thromboembolic com-
plications occurred (12 of initial 43 patients on combi-
nation arm) and thromboprophylaxis was subsequently
recommended. Figg et al also reported on the results of
a phase II study of 20 patients treated with weekly doce-
taxel, thalidomide 200 mg daily, and estramustine [49].
The patient population had metastatic disease that was
androgen-insensitive but chemotherapy-naïve. 90%
demonstrated ≥ 50% PSA declines; two of 10 patients
with measurable disease had a partial response; and
time to progression was 7.2 months.
The activity of thalidomide, bevacizumab, and doce-
taxel in 60 chemotherapy-naïve patients with metastatic
castrate-resistant prostate cancer was reported by Ning
et al [50]. Patients were given docetaxel at 75 mg/m2
every 21 days; bevacizumab 15 mg/kg every 21 days;
thalidomide 200 mg daily; prednisone 5 mg twice daily;
and thromboprophylaxis with enoxaparin. 90% of
patients had PSA decline of ≥50% and progression free
survival was estimated at 18.2 months. Median overall
survival was reported as 28.2 months. Although the
activity also compares favorably to the original TAX 327
data (18.9 month OS and 45% of patients with PSA
declines of ≥ 50% [4]), the comparison to historical con-
trols suffers from the usual limitations. In addition, tha-
lidomide toxicity required dose reduction in many
patients.
While there is suggestion of thalidomide activity in
both castrate-resistant and castrate-sensitive prostate
cancer, further phase III studies are needed to clarify its
role in prostate cancer therapy. In addition, follow-up of
the phase III thalidomide study in combination with
intermittent androgen deprivation may be revealing to
see if the differences seen in the time to PSA progres-
sion will ultimately result in differences in clinical
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endpoints such as metastatic disease progression or
overall survival; however, the cross-over design may
complicate analysis of longer-term endpoints. Notably,
lenalidomide, a thalidomide derivative with a more
favorable toxicity profile, is also being studied in pros-
tate cancer. Preliminary phase I-II results as a single
agent have been reported in abstract form [51]. Lenali-
domide is also being evaluated in combination with
both chemotherapy and other anti-angiogenesis agents.
Given previous results discussed with a thalidomide,
bevacizumab, docetaxel combination [50], the NCI is
sponsoring a phase II study to evaluate toxicity and effi-
cacy of the less-toxic lenalidomide, in combination with
bevacizumab, docetaxel and prednisone (NCT00942578).
Finally, a phase III study of the combination of doce-
taxel with and without lenalidomide is currently under-
way (NCT00988208). A summary of the clinical trials
investigating VEGF-targeting therapies and thalidomide-
derivatives in prostate cancer is presented in Table 1.
PDGF-targeted therapy
As mentioned above, PDGF has angiogenic properties.
In addition to the effects of PDGF on angiogenesis,
there is other evidence suggesting a role for PDGF-
targeted therapy in the treatment of prostate cancer.
PDGFR was seen as the most commonly amplified tran-
script when aspirates from prostate cancer bone metas-
tases were evaluated for amplification of tyrosine kinase
receptors, and overexpression of PDGF in prostate can-
cer bone metastases was confirmed by immunohisto-
chemistry [52]. PDGF inhibitors have also been shown
to reduce interstitial fluid pressure in tumors, enhancing
delivery of chemotherapy to tumors [53]. Unfortunately,
clinical trials using PDGF-targeting therapy in patients
with prostate cancer have been disappointing.
Imatinib is a multi-tyrosine kinase inhibitor with anti-
PDGFR activity. It is used clinically in the setting of
chronic myelogenous leukemia and GI stromal tumors,
where inhibition of the bcr-abl and c-kit tyrosine kinase
receptors has significant clinical effects. Imatinib has
been used as a single agent in three phase II studies in
the setting of biochemically relapsed prostate cancer
[54-56]. Lin et al studied imatinib at a dose of 400 mg
orally twice daily in 20 patients with nonmetastatic
prostate cancer and rising PSA. Only one patient had
PSA decline of ≥ 50%. Overall, there was no significant
change in PSA doubling time after imatinib treatment.
In addition, 11 men withdrew from the study because of
toxicity. The trial was stopped early because grade 3-4
toxicity events were higher than the predetermined tar-
get of 5%. Rao et al also reported results of a phase II
study using imatinib 400 mg orally twice daily in 21
patients with PSA-only recurrence. This trial was
stopped early because five patients were noted to have
unusually fast PSA rise while on study. Toxicity was
also moderate, with six patients withdrawing consent for
toxicity. No patient was seen to have a PSA decline of ≥
50%. Bajaj et al also reported their results using imatinib
400 mg orally twice daily in a similar patient population.
PSA declines of ≥ 50% were seen in only two of 27
patients (3.7%), with the majority demonstrating PSA
progression (74.1%). In addition, toxicity was not infre-
quent, with grade 3 toxicities seen in approximately 20%
of patients. Seven patients withdrew from the study for
toxicity. Taken together, these three phase II studies
demonstrate that imatinib 400 mg twice daily has little
effect on PSA kinetics and is too toxic to consider as
therapy in biochemical recurrence, which is typically an
asymptomatic population.
The effect of PDGF-targeting has also been evaluated
in the metastatic setting. The effect of an intravenous
PDGFR inhibitor, SU101 (leflunomide) in men with
androgen-independent prostate cancer was assessed in a
phase II study that enrolled 44 men [57]. All patients
had metastatic disease and half the patients had received
previous chemotherapy. SU101 was given intravenously
with a 4 day loading dose followed by weekly infusions
(all but one patient received a dose of 400 mg/m2/day).
Three patients evaluable for PSA response had PSA
decline of ≥ 50%. One of these patients had a dramatic
decline from 293 to 0.3 ng/mL. This same patient was
noted to have an objective partial response, out of 19
patients with measurable disease. Although the clinical
results were not encouraging, the observation of an
objective response with SU101 therapy suggests the pos-
sibility that there may be a small subset of prostate can-
cer that will benefit from PDGF signaling inhibition.
Finally, imatinib has been combined with docetaxel in
a randomized phase II study in men with metastatic
androgen-independent prostate cancer [58]. 144 patients
were enrolled and randomized to receive either imatinib
600 mg daily or placebo. In addition, patients received
docetaxel 30 mg intravenously on days 1, 8, 15, and 22
of a 42 day cycle. Most men were chemotherapy-naïve
(approximately 70% in both groups). The PSA response
rate (declines ≥ 50%), progression-free survival, and
overall survival were not significantly different in the
imatinib group, and in fact, generally favored the pla-
cebo arm. The trial was stopped early because of toxicity
concerns, with gastrointestinal toxicities predominating.
Other approaches
In addition to the agents discussed above, other angio-
genesis inhibitors are actively being evaluated in prostate
cancer. Aflibercept, also called VEGF-trap, is a fusion
protein that combines the Fc portion of human IgG1
with the VEGFR-1 and -2 ligand binding domains. Afli-
bercept binds VEGF-A, VEGF-B and Placental-GF,
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competitively inhibiting VEGF receptor activation. The
VENICE study is currently enrolling 1200 patients with
castrate-resistant prostate cancer in a Phase III evalua-
tion of docetaxel/prednisone with and without afliber-
cept to definitively answer the question whether this
drug has an additive benefit to docetaxel-based che-
motherapy in prostate cancer. Other tyrosine kinase
inhibitors are also being considered for use in prostate
cancer. For example, AZD2171, also known as cediranib,
is an oral tyrosine kinase inhibitor that potently targets
VEGFR-1, -2 and -3 while also having lesser effects on
PDGFR and c-kit [59]. This drug is currently being stu-
died in metastatic castrate-resistant prostate cancer in
Phase II clinical trials. Preliminary reports of responding
prostate cancer patients on phase I and phase II studies
[60,61], suggested that PSA response did not correlate
well with partial responses seen on imaging, reminiscent
of similar experiences with sorafenib. In addition, the
tyrosine kinase inhibitor pazopanib, which targets VEGF
and PDGF receptors [62], is currently undergoing
Table 1 A summary of clinical trials with angiogenesis inhibitors in prostate cancer
Drug(s) N Population Clinical benefit Ref
VEGF monoclonal antibody
Bevacizumab 10 mg/kg q2wk × 6 Ph
II
15 mCRPC 4 of 15 had PSA decline < 50%
No PSA decline > 50%
No objective responses
[30]
Bevacizumab 15 mg/kg d2
Docetaxel 70 mg/m2 q3wk
Estramustine 280 mg TID d1-5
PhII 79 mCRPC PSA response > 50% in 77% of patients
42% with radiographic partial response
[32,33]
Bevacizumab 10 mg/kg q3wk
Docetaxel 60 mg/m2
PhII 20 mCRPC, docetaxel
failure
PSA response > 50% in 55% of patients
3 of 8 patients had objective radiographic response
[34]
Tyrosine Kinase Inhibitor
Sorafenib 400 mg BID PhII 22 mCRPC, No PSA decline > 50%
No objective radiographic responses
[36]
Sorafenib 400 mg BID PhII 28 CRPC,
docetaxel-naïve
PSA response > 50% in 1 patient (3.6%)
No objective radiographic responses
[37]
Sorafenib 400 mg BID PhII 55 CRPC,
docetaxel-naïve
PSA response > 50% in 2 patients (3.6%)
No objective radiographic responses
[38]
Sunitinib 50 mg/day × 4 wks of 6 wk
cycle
PhII 34 CRPC PSA response > 50% in 2 patients (5.9%)
1 objective radiographic response (2.9%)
[40]
Thalidomide
Thalidomide 200 mg/day PhII 63 CRPC PSA response > 50% in 14% of patients
No objective radiographic responses
[43]
Thalidomide 200 mg/day PhIII 159 bCSPC Crossover design, time to restarting intermittent ADT
Time to PSA progression favored thalidomide group
15 v 9.6 mo, p = 0.21 in first phase
17.1 v 6.6 mo, p = 0002 in second phase
[45]
Thalidomide 200 mg/day
Docetaxel 30 mg/m2 d1, 8, 15 of 28
day cycle
rPhII 75 mCRPC,
docetaxel-naïve
PSA response > 50% in 53% of thalidomide group vs
PSA response > 50% in 37% of control group (p = 0.32)
OS of 25.9 mo in thalidomide group vs
OS of 14.7 mo in control group (p = 0.0407)
[46-48]
Thalidomide 200 mg/day
Docetaxel 30 mg/m2 d1, 8, 15
Estramustine TID d1-3, 8-10, 15-17 of
28 day cycle
PhII 20 mCRPC,
docetaxel-naïve
PSA response > 50% in 90% of patients [49]
Thalidomide 200 mg/day
Docetaxel 75 mg/m2 q3wk
Bevacizumab 15 mg/kg q3wk
PhII 60 mCRPC,
docetaxel-naïve
PSA response > 50% in 88% of patients [50]
Pending Phase III studies
Docetaxel + Prednisone +/-
Bevacizumab
PhIII 1050 mCRPC,
docetaxel-naïve
Preliminary results indicate no benefit in overall survival for
bevacizumab arm
[35]
Docetaxel + Prednisone +/-
Lenalidomide
PhIII 1015* mCRPC,
docetaxel-naïve
Results pending NCT00988208
Prednisone +/- Sunitinib PhIII 819* mCRPC, docetaxel
failure
Results pending NCT00676650
*Anticipated Enrollment. mCRPC - metastatic castrate-resistant Prostate Cancer. bCRPC - biochemically recurrent castrate-resistant prostate cancer. bCSPC -
biochemically recurrent castrate-sensitive prostate cancer.
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clinical investigation in prostate cancer in the castrate-
resistant setting (NCT00454571, NCT00486642,
NCT00945477).
Another agent with anti-angiogenic properties that is
being evaluated in clinical trials is tasquinimod. This
compound was initially identified on the observation
that linomide, an agent being investigated in multiple
sclerosis, had anti-angiogenic properties [63]. Since the
original compound was found to be toxic in clinical
trials, analogs were screened for anti-angiogenic activity.
Although its mechanism of anti-angiogenic activity is
not entirely clear, tasquinimod was identified as a lead
compound. Subsequently, it was shown that tasquini-
mod has anti-tumor activity in prostate cancer xenograft
models and was well-tolerated in phase I studies [63,64].
Most recently, results of a randomized phase II study
were reported in abstract form [65]. 206 patients with
asymptomatic, metastatic CRPC were assigned in a 2:1
ratio to either oral tasquinimod or placebo. Tasquini-
mod met the primary endpoint of the study, which was
a superior progression-free proportion at six months
compared to placebo (69% vs. 34%, p < 0.0001). In addi-
tion, median progression-free survival also favored tas-
quinimod (7.6 vs. 3.2 months, p = 0.0009). Progression
was defined only clinically, without the use of PSA cri-
teria. Notably, tasquinimod had no appreciable effect on
PSA compared to placebo. Toxicity included on-target
toxicity such as vascular events, but was felt to be man-
ageable by investigators. Overall, the results of this trial
were felt to justify the planning of a phase III study.
In addition to the approaches just considered, review
of known angiogenesis mechanisms suggests other ways
to target this process for clinical benefit. In fact, other
anti-angiogenesis approaches are being pursued in can-
cer, although they are not as mature in their application
for prostate cancer. For example, as discussed above, the
angiogenic switch is triggered by a balance of pro- and
anti-angiogenic factors. We have discussed in great
detail a single pro-angiogenic factor, the VEGF family.
However, there are naturally occurring anti-angiogenesis
factors which exist, such as endostatin and thrombos-
pondin. Compounds which mimic the action of these
natural anti-angiogenic factors are also being evaluated
for use in solid malignancies [66,67]. In addition, the
production of pro-angiogenesis factors is also being tar-
geted with HIF-1a inhibitors [68].
As it has become clearer that resistance to angiogen-
esis inhibition can present a clinical challenge, targeting
the process from multiple angles may provide synergy
or additive effects able to overcome resistance. Results
of the combination of docetaxel, bevacizumab and thali-
domide in prostate cancer are encouraging, as discussed
above [50]. Dual inhibition is also being investigated in
a phase I study with the combination of sorafenib and
bevacizumab (NCT00098592). However, this approach
of dual targeting will require proceeding with caution to
avoid unexpected toxicities. A phase I strategy of dual
inhibition using sunitinib and bevacizumab in renal cell
carcinoma was complicated by the development of fre-
quent severe hypertension and microangiopathic hemo-
lytic anemia associated with reversible posterior
leukoencephalopathy syndrome [69]. Although microan-
giopathic hemolytic anemia and reversible posterior leu-
koencephalopathy syndrome were not reproduced in an
independent phase I combination study performed in all
tumor types, toxicity-related dose modifications were
frequently necessary [70]. Various strategies have been
proposed to mitigate the toxicity of anti-angiogenic
combinations. These include monitoring pharmacody-
namic endpoints instead of escalating to maximally tol-
erated dose of each agent, or limiting exposure to a
drug by restricting its administration to a short pulse at
a critical point in the chemotherapy cycle.
Conclusion
Angiogenesis appears to play a role in the progression of
prostate cancer. After several decades of investigation,
angiogenesis inhibitor therapy is finally being evaluated
in prostate cancer patients. While anti-angiogenic agents
appear to be a promising addition to prostate cancer
therapies, challenges in clinical trial design and interpre-
tation have prevented the rapid adoption of these agents
into clinical practice. Among these challenges is the fact
that certain anti-angiogenic agents can increase PSA in
the face of evidence of disease response. To address this
concern, the 2008 Prostate Cancer Clinical Trials Working
Group (PCWG-2) has recommended specific endpoints
for cytostatic therapies, including anti-angiogenesis agents,
which emphasize time-to-event endpoints [71]. Moreover,
PCWG-2 stresses the importance of radiographic and
symptomatic progression when making clinical trial treat-
ment decisions and discourages investigators from discon-
tinuing treatment on the basis of isolated PSA
progression. Attention to such clinical endpoints may
limit premature discontinuation of therapy, which has
been cited as a contributor to the negative results of
CALGB 90401. Future clinical development of anti-angio-
genic therapy will benefit from attention to these design
considerations. So far, evidence that the use of angiogen-
esis inhibitors results in meaningful clinical benefit for
prostate cancer remains elusive, including recent data
from CALGB 90401. Nonetheless, continued enthusiasm
for anti-angiogenesis therapies in prostate cancer has been
justified by signs of activity on CALGB 90401, as well as
encouraging phase II data, including the combination of
bevacizumab and thalidomide with docetaxel [50]. Final
results from several Phase III studies in the castrate-
sensitive, docetaxel-naïve, and docetaxel-refractory settings
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are still pending. Results from these clinical trials will
hopefully clarify the role of angiogenesis inhibitors in the
arsenal of prostate cancer therapies.
List of Abbreviations
CRPC, Castrate-resistant prostate cancer; ATP, Adenosine triphosphate;
bCRPC, biochemically-recurrent castrate-resistant prostate cancer; bCSPC,
biochemically-recurrent castrate-sensitive prostate cancer; CALGB, Cancer
and Leukemia Group B; FDA, Food and Drug Administration; GnRH,
Gonadotropin Releasing Hormone; HIF, Hypoxia-inducible factor; mCRPC,
metastatic Castrate-resistant prostate cancer; NCI, National Cancer Institute;
PDGF, Platelet-derived growth factor; PDGFR, Platelet-derived growth factor
receptor; PSA, Prostate-specific antigen; PCWG2, Prostate Cancer Clinical
Trials Working Group 2; RECIST, Response evaluation criteria in solid tumors;
VEGF, Vascular endothelial growth factor; VEGFR, Vascular endothelial growth
factor receptor; VHL, Von Hippel Lindau.
Competing interests
CH declares that she has no competing interests. EH reports receiving
research funding from Astra Zeneca, GlaxoSmithKline and Pfizer.
Authors’ contributions
CH drafted the manuscript. EH conceived of the manuscript and performed
critical revisions. Both authors read and approved of the final manuscript.
Acknowledgements
The authors would like to thank Dr. Ding Wang for his comments and
review of the manuscript.
Author details
1Department of Internal Medicine, Henry Ford Hospital, CFP 559, 2799 West
Grand Blvd, Detroit, MI 48202, USA. 2Karmanos Cancer Institute and Wayne
State University School of Medicine, 4234 KCI, 4100 John R, Detroit, MI,
48201, USA.
Received: 19 May 2010 Accepted: 2 August 2010
Published: 2 August 2010
References
1. Drugs@FDA. [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.
cfm].
2. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D,
Winer EP, Vogelzang NJ: Hydrocortisone with or without mitoxantrone in
men with hormone-refractory prostate cancer: results of the cancer and
leukemia group B 9182 study. J Clin Oncol 1999, 17:2506-2513.
3. Osoba D, Tannock IF, Ernst DS, Neville AJ: Health-related quality of life in
men with metastatic prostate cancer treated with prednisone alone or
mitoxantrone and prednisone. J Clin Oncol 1999, 17:1654-1663.
4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S,
Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA:
Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME,
Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D,
Crawford ED: Docetaxel and estramustine compared with mitoxantrone
and prednisone for advanced refractory prostate cancer. N Engl J Med
2004, 351:1513-1520.
6. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med
1971, 285:1182-1186.
7. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR,
Schwartz MA, Benson AB: Bevacizumab in combination with oxaliplatin,
fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic
colorectal cancer: results from the Eastern Cooperative Oncology Group
Study E3200. J Clin Oncol 2007, 25:1539-1544.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J,
Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G,
Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil,
and leucovorin for metastatic colorectal cancer. N Engl J Med 2004,
350:2335-2342.
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R,
Johnson DH: Paclitaxel-carboplatin alone or with bevacizumab for non-
small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
10. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T,
Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone
for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
11. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C,
Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I,
Jagiello-Gruszfeld A, Moore N: Bevacizumab plus interferon alfa-2a for
treatment of metastatic renal cell carcinoma: a randomised, double-
blind phase III trial. Lancet 2007, 370:2103-2111.
12. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE,
Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J,
Zheng M, Cloughesy T: Bevacizumab alone and in combination with
irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733-4740.
13. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M,
Butman JA, Camphausen K, Park J, Albert PS, Fine HA: Phase II trial of
single-agent bevacizumab followed by bevacizumab plus irinotecan at
tumor progression in recurrent glioblastoma. J Clin Oncol 2009,
27:740-745.
14. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat
Rev Cancer 2003, 3:401-410.
15. Kerbel RS: Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
16. Liang WC, Wu X, Peale FV, Lee CV, Meng YG, Gutierrez J, Fu L, Malik AK,
Gerber HP, Ferrara N, Fuh G: Cross-species vascular endothelial growth
factor (VEGF)-blocking antibodies completely inhibit the growth of
human tumor xenografts and measure the contribution of stromal
VEGF. J Biol Chem 2006, 281:951-961.
17. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin
Oncol 2004, 22:4991-5004.
18. Andrae J, Gallini R, Betsholtz C: Role of platelet-derived growth factors in
physiology and medicine. Genes Dev 2008, 22:1276-1312.
19. George DJ: Receptor tyrosine kinases as rational targets for prostate
cancer treatment: platelet-derived growth factor receptor and imatinib
mesylate. Urology 2002, 60:115-121, discussion 122..
20. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy.
Nat Rev Cancer 2008, 8:592-603.
21. Abdollahi A, Folkman J: Evading tumor evasion: current concepts and
perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 2010,
13:16-28.
22. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP,
Kreutzer DL: Vascular endothelial growth factor (VEGF) expression in
human prostate cancer: in situ and in vitro expression of VEGF by
human prostate cancer cells. J Urol 1997, 157:2329-2333.
23. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K: Vascular
endothelial growth factor (VEGF) expression in prostatic tumours and its
relationship to neuroendocrine cells. Br J Cancer 1996, 74:910-916.
24. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR:
Plasma levels of vascular endothelial growth factor are increased in
patients with metastatic prostate cancer. Urology 1999, 54:523-527.
25. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ,
Kantoff PW: Prognostic significance of plasma vascular endothelial
growth factor levels in patients with hormone-refractory prostate cancer
treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001,
7:1932-1936.
26. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P,
Shuman MA, Small EJ: Vascular endothelial growth factor and basic
fibroblast growth factor urine levels as predictors of outcome in
hormone-refractory prostate cancer patients: a cancer and leukemia
group B study. Cancer Res 2001, 61:2533-2536.
27. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J: Tumor
angiogenesis correlates with metastasis in invasive prostate carcinoma.
Am J Pathol 1993, 143:401-409.
28. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H,
Bostwick DG: Role of microvessel density in predicting recurrence in
pathologic Stage T3 prostatic adenocarcinoma. Urology 1999, 54:479-485.
29. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S: Effects of
sustained antiangiogenic therapy in multistage prostate cancer in
TRAMP model. Cancer Res 2007, 67:5789-5797.
30. Reese DM, Fratesi P, Corry M, Novotny W, Holmgren E, Small EJ: A Phase II
Trial of Humanized Anti-Vascular Endothelial Growth Factor Antibody for
Hwang and Heath Journal of Hematology & Oncology 2010, 3:26
http://www.jhoonline.org/content/3/1/26
Page 10 of 12
the Treatment of Androgen-Independent Prostate Cancer. The Prostate
Journal 2001, 3:65-70.
31. Iacobelli S: Hormone-refractory prostate cancer responding to
bevacizumab. Int J Urol 2008, 15:754.
32. J Picus SH, Rini B, Vogelzang N, Whang Y, Kaplan E, Kelly W, Small E: The
use of bevacizumab (B) with docetaxel (D) and estramustine (E) in
hormone refractory prostate cancer (HRPC): Initial results of CALGB
90006 [abstract]. Proc Am Soc Clin Oncol 2003, 22:abstr 1578.
33. Picus J: Docetaxel/bevacizumab (Avastin) in prostate cancer. Cancer Invest
2004, 22:60.
34. Di Lorenzo G, Figg WD, Fossa SD, Mirone V, Autorino R, Longo N,
Imbimbo C, Perdona S, Giordano A, Giuliano M, Labianca R, De Placido S:
Combination of bevacizumab and docetaxel in docetaxel-pretreated
hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008,
54:1089-1094.
35. Kelly WK, Halabi S, Carducci MA, George DJ, Mahoney JF, Stadler WM,
Morris MJ, Kantoff P, Monk JP III, Small EJ: A randomized, double-blind,
placebo-controlled phase III trial comparing docetaxel, prednisone, and
placebo with docetaxel, prednisone, and bevacizumab in men with
metastatic castration-resistant prostate cancer (mCRPC): Survival results
of CALGB 90401. J Clin Oncol 2010, 28:18s, (suppl; abstr LBA4511)..
36. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ,
Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC,
Figg WD: A phase II clinical trial of sorafenib in androgen-independent
prostate cancer. Clin Cancer Res 2008, 14:209-214.
37. Chi KN, Ellard SL, Hotte SJ, Czaykowski P, Moore M, Ruether JD, Schell AJ,
Taylor S, Hansen C, Gauthier I, Walsh W, Seymour L: A phase II study of
sorafenib in patients with chemo-naive castration-resistant prostate
cancer. Ann Oncol 2008, 19:746-751.
38. Steinbild S, Mross K, Frost A, Morant R, Gillessen S, Dittrich C, Strumberg D,
Hochhaus A, Hanauske AR, Edler L, Burkholder I, Scheulen M: A clinical
phase II study with sorafenib in patients with progressive hormone-
refractory prostate cancer: a study of the CESAR Central European
Society for Anticancer Drug Research-EWIV. Br J Cancer 2007,
97:1480-1485.
39. Song IC, Lim JS, Yun HJ, Kim S, Kang DY, Lee HJ: Biochemical and
pathological response of prostate cancer in a patient with metastatic
renal cell carcinoma on sunitinib treatment. Jpn J Clin Oncol 2009,
39:833-836.
40. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K,
Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR: Phase II study of
sunitinib in men with advanced prostate cancer. Ann Oncol 2009,
20:913-920.
41. D’Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor
of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082-4085.
42. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, Pisters LL,
McDonnell TJ, Logothetis CJ: Initial modulation of the tumor
microenvironment accounts for thalidomide activity in prostate cancer.
Clin Cancer Res 2007, 13:1224-1231.
43. Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM,
Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S,
Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E: A randomized phase II
trial of thalidomide, an angiogenesis inhibitor, in patients with
androgen-independent prostate cancer. Clin Cancer Res 2001, 7:1888-1893.
44. Dixon SC, Kruger EA, Bauer KS, Figg WD: Thalidomide up-regulates
prostate-specific antigen secretion from LNCaP cells. Cancer Chemother
Pharmacol 1999, 43(Suppl):S78-84.
45. Figg WD, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB, Petrylak DP,
Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright JJ, Sartor O,
Dahut WL: A double-blind randomized crossover study of oral
thalidomide versus placebo for androgen dependent prostate cancer
treated with intermittent androgen ablation. J Urol 2009, 181:1104-1113,
discussion 1113..
46. Figg WD, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K, Hamilton M,
Parker C, Kruger EA, Pluda J, Dahut WL: A randomized phase II trial of
docetaxel (taxotere) plus thalidomide in androgen-independent prostate
cancer. Semin Oncol 2001, 28:62-66.
47. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ,
Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD: Randomized
phase II trial of docetaxel plus thalidomide in androgen-independent
prostate cancer. J Clin Oncol 2004, 22:2532-2539.
48. Figg WD, Retter A, Steinberg SM, Dahut WL: In reply. J Clin Oncol 2005,
23:2113-2114.
49. Figg WD, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P, Wright JJ,
Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E, Chen C, Dahut W:
Pre-clinical and clinical evaluation of estramustine, docetaxel and
thalidomide combination in androgen-independent prostate cancer. BJU
Int 2007, 99:1047-1055.
50. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL,
Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC,
Figg WD, Dahut WL: Phase II trial of bevacizumab, thalidomide,
docetaxel, and prednisone in patients with metastatic castration-
resistant prostate cancer. J Clin Oncol 2010, 28:2070-2076.
51. Sinibaldi VJ, Carducci MA, Moore-Cooper S, George B, Denmeade S,
Drake CG, Walczak J, Pili R, Zahurak ML, Eisenberger MA: A randomized
double blind phase I-II study to determine the tolerability/efficacy of
two different doses of lenalidomide (L), CC- 5013, in biochemically
relapsed (BR) prostate cancer (PC) patients (pts) (M0) after local
treatment (LT) [abstract]. J Clin Oncol (Meeting Abstracts) 2009, 27:s5130.
52. Chott A, Sun Z, Morganstern D, Pan J, Li T, Susani M, Mosberger I,
Upton MP, Bubley GJ, Balk SP: Tyrosine kinases expressed in vivo by
human prostate cancer bone marrow metastases and loss of the type 1
insulin-like growth factor receptor. Am J Pathol 1999, 155:1271-1279.
53. Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH,
Ostman A: Inhibition of PDGF receptor signaling in tumor stroma
enhances antitumor effect of chemotherapy. Cancer Res 2002,
62:5476-5484.
54. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L,
Small EJ: A phase II trial of imatinib mesylate in patients with
biochemical relapse of prostate cancer after definitive local therapy. BJU
Int 2006, 98:763-769.
55. Rao K, Goodin S, Levitt MJ, Dave N, Shih WJ, Lin Y, Capanna T, Doyle-
Lindrud S, Juvidian P, DiPaola RS: A phase II trial of imatinib mesylate in
patients with prostate specific antigen progression after local therapy
for prostate cancer. Prostate 2005, 62:115-122.
56. Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR,
Carducci MA, Eisenberger MA, DeWeese TL: Phase II study of imatinib
mesylate in patients with prostate cancer with evidence of biochemical
relapse after definitive radical retropubic prostatectomy or radiotherapy.
Urology 2007, 69:526-531.
57. Ko YJ, Small EJ, Kabbinavar F, Chachoua A, Taneja S, Reese D, DePaoli A,
Hannah A, Balk SP, Bubley GJ: A multi-institutional phase ii study of
SU101, a platelet-derived growth factor receptor inhibitor, for patients
with hormone-refractory prostate cancer. Clin Cancer Res 2001, 7:800-805.
58. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM,
Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L,
Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ: Platelet-derived growth factor
receptor inhibition and chemotherapy for castration-resistant prostate
cancer with bone metastases. Clin Cancer Res 2007, 13:5816-5824.
59. Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR,
Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ,
Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL,
Taylor ST, Cooper L, Beck S, Jurgensmeier JM, Ogilvie DJ: AZD2171: a
highly potent, orally bioavailable, vascular endothelial growth factor
receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer
Res 2005, 65:4389-4400.
60. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C,
Small EJ: Phase I dose escalation and pharmacokinetic study of
AZD2171, an inhibitor of the vascular endothelial growth factor receptor
tyrosine kinase, in patients with hormone refractory prostate cancer
(HRPC). Invest New Drugs 2007, 25:445-451.
61. Karakunnel JJ, Gulley JL, Arlen PM, Mulquin M, Wright JJ, Turkbey IB,
Choyke P, Ahlers CM, Figg WD, Dahut WL: Phase II trial of cediranib
(AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer
(CRPC) [abstract]. J Clin Oncol (Meeting Abstracts) 2008, 26:s5136.
62. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase
inhibitor. Curr Oncol Rep 2007, 9:115-119.
63. Bratt O, Haggman M, Ahlgren G, Nordle O, Bjork A, Damber JE: Open-label,
clinical phase I studies of tasquinimod in patients with castration-
resistant prostate cancer. Br J Cancer 2009, 101:1233-1240.
64. Dalrymple SL, Becker RE, Isaacs JT: The quinoline-3-carboxamide anti-
angiogenic agent, tasquinimod, enhances the anti-prostate cancer
Hwang and Heath Journal of Hematology & Oncology 2010, 3:26
http://www.jhoonline.org/content/3/1/26
Page 11 of 12
efficacy of androgen ablation and taxotere without effecting serum PSA
directly in human xenografts. Prostate 2007, 67:790-797.
65. Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Björk A, Forsberg G,
Carducci MA, Armstrong AJ: A randomized, multicenter, international
phase II study of tasquinimod in chemotherapy naïve patients with
metastatic castrate-resistant prostate cancer (CRPC). J Clin Oncol 2010,
28:15s, (suppl; abstr 4510)..
66. Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA,
Iannone M, Stopeck AT: A phase 1 trial of 2 dose schedules of ABT-510,
an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with
advanced cancer. Cancer 2008, 113:3420-3429.
67. Folkman J: Antiangiogenesis in cancer therapy–endostatin and its
mechanisms of action. Experimental Cell Research 2006, 312:594-607.
68. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer
biology and therapeutics. Oncogene 2010, 29:625-634.
69. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S,
Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ: Phase I trial of
bevacizumab plus escalated doses of sunitinib in patients with
metastatic renal cell carcinoma. J Clin Oncol 2009, 27:1432-1439.
70. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T,
Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A,
Dreicer R: A phase I study of sunitinib plus bevacizumab in advanced
solid tumors. Clin Cancer Res 2009, 15:6277-6283.
71. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA,
Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P,
Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A,
Hussain M: Design and end points of clinical trials for patients with
progressive prostate cancer and castrate levels of testosterone:
recommendations of the Prostate Cancer Clinical Trials Working Group. J
Clin Oncol 2008, 26:1148-1159.
doi:10.1186/1756-8722-3-26
Cite this article as: Hwang and Heath: Angiogenesis inhibitors in the
treatment of prostate cancer. Journal of Hematology & Oncology 2010
3:26.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hwang and Heath Journal of Hematology & Oncology 2010, 3:26
http://www.jhoonline.org/content/3/1/26
Page 12 of 12
